| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/26/2023 | -16.48% | Goldman Sachs | $16 → $26 | Maintains | Neutral |
| 01/03/2023 | 134.5% | HC Wainwright & Co. | $85 → $73 | Maintains | Buy |
| 12/01/2022 | -48.6% | Goldman Sachs | → $16 | Upgrades | Sell → Neutral |
| 11/16/2022 | -42.18% | Mizuho | $19 → $18 | Maintains | Buy |
| 11/11/2022 | -19.69% | Guggenheim | $28 → $25 | Maintains | Buy |
| 11/11/2022 | 144.14% | Canaccord Genuity | $75 → $76 | Maintains | Buy |
| 11/11/2022 | -42.18% | Mizuho | $19 → $18 | Maintains | Buy |
| 08/24/2022 | 173.05% | HC Wainwright & Co. | $110 → $85 | Maintains | Buy |
| 07/07/2022 | -38.97% | Mizuho | → $19 | Initiates Coverage On | → Buy |
| 05/23/2022 | 253.36% | HC Wainwright & Co. | $134 → $110 | Maintains | Buy |
| 04/14/2022 | 330.45% | HC Wainwright & Co. | $130 → $134 | Maintains | Buy |
| 03/14/2022 | 317.6% | HC Wainwright & Co. | $140 → $130 | Maintains | Buy |
| 02/16/2022 | -19.69% | UBS | $88 → $25 | Maintains | Buy |
| 11/15/2021 | -22.9% | Goldman Sachs | $55 → $24 | Downgrades | Buy → Sell |
| 06/28/2021 | 349.73% | HC Wainwright & Co. | $176 → $140 | Maintains | Buy |
| 06/23/2021 | 301.54% | Truist Securities | $128 → $125 | Maintains | Buy |
| 06/01/2021 | 465.37% | HC Wainwright & Co. | $170 → $176 | Maintains | Buy |
| 05/11/2021 | 446.1% | HC Wainwright & Co. | $175 → $170 | Maintains | Buy |
| 04/09/2021 | 140.93% | Berenberg | → $75 | Initiates Coverage On | → Buy |
| 04/01/2021 | 205.17% | Canaccord Genuity | $110 → $95 | Maintains | Buy |
| 04/01/2021 | 307.97% | Truist Securities | $150 → $127 | Maintains | Buy |
| 04/01/2021 | 462.16% | HC Wainwright & Co. | $185 → $175 | Maintains | Buy |
| 02/01/2021 | 218.02% | UBS | → $99 | Initiates Coverage On | → Buy |
| 01/06/2021 | 494.28% | HC Wainwright & Co. | $175 → $185 | Maintains | Buy |
| 11/18/2020 | 253.36% | Canaccord Genuity | $108 → $110 | Maintains | Buy |
| 09/02/2020 | 163.41% | Jefferies | → $82 | Initiates Coverage On | → Buy |
| 08/17/2020 | 205.17% | BMO Capital | $104 → $95 | Maintains | Outperform |
| 08/17/2020 | 462.16% | HC Wainwright & Co. | $200 → $175 | Maintains | Buy |
| 07/21/2020 | 285.48% | Canaccord Genuity | $71 → $120 | Maintains | Buy |
| 07/20/2020 | 542.47% | HC Wainwright & Co. | $120 → $200 | Maintains | Buy |
| 07/13/2020 | 102.38% | B of A Securities | $53 → $63 | Reiterates | → Buy |
| 07/08/2020 | 285.48% | HC Wainwright & Co. | $95 → $120 | Reiterates | → Buy |
| 06/04/2020 | 224.45% | Guggenheim | → $101 | Initiates Coverage On | → Buy |
| 04/01/2020 | 44.56% | B of A Securities | → $45 | Initiates Coverage On | → Buy |
| 02/26/2020 | 205.17% | HC Wainwright & Co. | $30 → $95 | Reiterates | → Buy |
| 02/21/2020 | 118.44% | Canaccord Genuity | $27 → $68 | Maintains | Buy |
| 02/14/2020 | 381.85% | SunTrust Robinson Humphrey | $24 → $150 | Maintains | Buy |
| 01/08/2020 | -3.63% | HC Wainwright & Co. | $25 → $30 | Maintains | Buy |
| 11/12/2019 | -22.9% | SunTrust Robinson Humphrey | → $24 | Initiates Coverage On | → Buy |
| 05/03/2018 | -19.69% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 04/02/2018 | -51.81% | Barclays | → $15 | Initiates Coverage On | → Overweight |
| 04/02/2018 | -42.18% | UBS | → $18 | Initiates Coverage On | → Buy |
| 04/02/2018 | -26.12% | BMO Capital | → $23 | Initiates Coverage On | → Outperform |
| 04/02/2018 | -32.54% | Canaccord Genuity | → $21 | Initiates Coverage On | → Buy |
What is the target price for BioXcel Therapeutics (BTAI)?
The latest price target for BioXcel Therapeutics (NASDAQ: BTAI) was reported by Goldman Sachs on January 26, 2023. The analyst firm set a price target for $26.00 expecting BTAI to fall to within 12 months (a possible -16.48% downside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioXcel Therapeutics (BTAI)?
The latest analyst rating for BioXcel Therapeutics (NASDAQ: BTAI) was provided by Goldman Sachs, and BioXcel Therapeutics maintained their neutral rating.
When is the next analyst rating going to be posted or updated for BioXcel Therapeutics (BTAI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioXcel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioXcel Therapeutics was filed on January 26, 2023 so you should expect the next rating to be made available sometime around January 26, 2024.
Is the Analyst Rating BioXcel Therapeutics (BTAI) correct?
While ratings are subjective and will change, the latest BioXcel Therapeutics (BTAI) rating was a maintained with a price target of $16.00 to $26.00. The current price BioXcel Therapeutics (BTAI) is trading at is $31.13, which is out of the analyst's predicted range.